What caused the pre-market drop in AELIS.PA stock today?

The pre-market drop reflects profit-taking and sector sensitivity; AELIS.PA opened at €1.46 and fell to €1.37 with higher volume. Clinical-timing uncertainty and biotech peer moves amplified selling pressure.

What is Meyka AI’s outlook for AELIS.PA stock?

Meyka AI's forecast model projects a 12-month fair value of €3.06 for AELIS.PA stock, implying about 123.36% upside from €1.37. Forecasts are model-based and not guarantees.

Is AELIS.PA stock expensive relative to peers?

On price-to-sales (8.01) and price-to-book (3.06), AELIS.PA looks rich versus many small biotech peers. Negative EPS and high R&D intensity push valuation questions for near-term investors.

When are the next earnings or clinical announcements for AELIS.PA stock?

Aelis lists an earnings announcement on 30 March 2026. Clinical milestone dates for AEF0117 and AEF0217 remain primary catalysts and should be tracked alongside formal company updates.

EU Stocks

AELIS.PA stock down 6.16% to €1.37 pre-market on EURONEXT: model flags €3.06 fair value

ByHuzaifa Zahoor February 6, 2026February 6, 2026

AELIS.PA stock opened the pre-market session down 6.16% at €1.37 on EURONEXT after an early sell-off from an opening price of €1.46. Trading volume is elevated at 109,766 shares versus an average of 59,784, suggesting heavier interest. Investors are watching clinical-readout timing and cash runway for the Bordeaux-based biotech while sector weakness in Healthcare also weighs on performance.